Dr. Daniel K. Rogstad, MD

Dr. Rogstad practices at Loma Linda University Medical Center in Loma Linda, California, part of Seventh-day Adventist Church.

Dr. Rogstad's NPI, 1134358252, was assigned on July 10, 2009. Dr. Rogstad graduated from Loma Linda University School Of Medicine in 2009. Dr. Rogstad holds California license A136344.

Dr. Rogstad's primary practice is Loma Linda University Medical Center, at 11234 Anderson St, Loma Linda, CA 92354 in San Bernardino County. The practice phone is (909) 558-4000.

Dr. Rogstad's primary practice is Loma Linda University Medical Center in Loma Linda, California, part of Seventh-day Adventist Church. The medical group on file is Loma Linda University Faculty Medical Group (LLUFMG).

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rogstad practices. Vendor and product names are available with a free account.

Infectious disease is Dr. Rogstad's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Rogstad is board certified in infectious disease by the American Board of Internal Medicine. Dmand AI has Dr. Rogstad's licenses on file in 2 states: California and Minnesota.

Dmand AI lists pneumonia among the conditions Dr. Rogstad treats.

CMS data shows 87 Medicare services from Dr. Rogstad across 5 procedure codes in 2024, for 58 Medicare patients. Medicare paid $8,524 for them.

CMS counts 58 Medicare patients who saw Dr. Rogstad in 2024. The largest group is 65 to 74, with 23 patients. 75% of them have high blood pressure, and 71% have high cholesterol. 55% are also on Medicaid. Their average risk score is 3.91, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rogstad's median patient age at 58, with 47% women.

In 2024, Dr. Rogstad wrote 110 Medicare Part D claims for 22 patients. 92% of them were for generic drugs. CMS names the drug for 60 of them, across 3 drugs with 11 or more claims each, at $11,378 in total drug cost. In 2023, CMS named 41 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Rogstad for performance year 2024, reported as part of a group. Dr. Rogstad accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rogstad as offering telehealth.

Dmand AI links 19 papers to Dr. Rogstad, published from 2007 to 2025. 2023 was the busiest year, with 3. The most frequent topics are DNA Damage, DNA Repair and Gas Chromatography-Mass Spectrometry. Dr. Rogstad has published most often in Biochemistry. Dr. Rogstad's most frequent co-authors are Gregory Cheek, MD, Ara A. Chrissian, MD and Brian Shigenobu Furukawa, MD.

CMS Open Payments shows 5 general payments to Dr. Rogstad from 2 drug and device companies from 2016 to 2022. Food and beverage make up the largest share, 73% of the total. Allergan Inc. paid the most, $54.

Dr. Rogstad graduated from Loma Linda University School Of Medicine in 2009. Dr. Rogstad is a member of AOA.

Dr. Rogstad is in network with 17 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.